Paid Clinical Trials Murfreesboro
Discover 1,116 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
PovorcitinibA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Sponsor:
Incyte Corporation
Location:
Code:
NCT06516952
Conditions
Prurigo Nodularis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Povorcitinib
Placebo
Sleep QualityEnhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
Sponsor:
University of Alabama, Tuscaloosa
Location:
Code:
NCT05820919
Conditions
Alzheimer Disease
Dementia
Sleep Disorder
Sleep Disturbance
Eligibility Criteria
Sex: All
Age: 50+
Healthy Volunteers: Not accepted
Interventions
LOCK Sleep Program
No intervention (control period/baseline data collection)
DazodalibepA Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sj├╢gren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
Sponsor:
Amgen
Location:
Code:
NCT06104124
Conditions
Sjogren's Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Dazodalibep
Placebo
VDPHL01Efficacy and Safety of VDPHL01 in Males with AGA
Sponsor:
Veradermics, Inc.
Location:
Code:
NCT06724614
Conditions
Androgenetic Alopecia
AGA
Male Pattern Baldness
Eligibility Criteria
Sex: Male
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
VDPHL01
Placebo
Dapirolizumab PegolA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Sponsor:
UCB Biopharma SRL
Location:
Code:
NCT06617325
Conditions
Systemic Lupus Erythematosus
Eligibility Criteria
Sex: All
Age: 16+
Healthy Volunteers: Not accepted
Interventions
DZP
Placebo
Interested in new trials?
Get alerts for new trials in your area by subscribing now
EltrekibartA Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06046729
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Eltrekibart
Placebo
BaricitinibA Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT05723198
Conditions
Areata Alopecia
Alopecia
Hypotrichosis
Hair Diseases
Skin Diseases
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Baricitinib
Placebo
AmlitelimabLong-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Sponsor:
Sanofi
Location:
Code:
NCT05492578
Conditions
Dermatitis Atopic
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Amlitelimab
Topical corticosteroids
Topical calcineurin inhibitors
Oral corticosteroids
Upadacitinib vs. DupilumabA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Sponsor:
AbbVie
Location:
Code:
NCT06461897
Conditions
Atopic Dermatitis
Eligibility Criteria
Sex: All
Age: 2 - 11
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Dupilumab
Observational StudyPatient Retrospective Outcomes (PRO)
Sponsor:
Boston Scientific Corporation
Location:
Code:
NCT01550575
Conditions
Chronic Pain
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Non Boston Scientific Systems
Boston Scientific Systems